Roche Launches Integrated Newborn Screening Test for SMA, SCID, and Sickle Cell Disease

Swiss pharmaceutical company Roche Holding AG announced the launch of a simultaneous newborn screening test for three serious genetic disorders: Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency (SCID), and Sickle Cell Disease (SCD).

Roche Diagnostics’ subsidiary, TIB MOLBIOL, has introduced the LightMix Newborn TREC/SMN1/HBB kit, a CE‑marked in‑vitro diagnostic assay for newborn screening that operates on standard LightCycler platforms.

Spinal Muscular Atrophy is a genetic neuromuscular disease that progressively degenerates spinal‑cord motor neurons, resulting in muscle weakness. Severe Combined Immunodeficiency comprises rare, life‑threatening genetic conditions marked by the absence of functional T cells, effectively leaving affected infants immunodeficient.

Sickle Cell Disease is an inherited hematologic disorder caused by a mutation in the HBB gene that leads to abnormal red blood cell shape and function.

The IVDR‑approved assay offers a ready‑to‑use diagnostic solution for private and academic hospital laboratories, facilitating early detection of these severe conditions. Prompt diagnosis empowers clinicians to inform families and expedite access to appropriate therapies.

Marcus Droege, CEO of TIB MOLBIOL, emphasized, “Every day matters for infants born with SMA or SCID. Detecting these diseases before symptoms appear can mean the difference between a child thriving and facing severe lifelong disability. By expanding our compliant newborn screening tools across Europe, we are helping labs transition to high‑precision solutions that prevent any critical diagnosis from being delayed.”

Source link